COVID-19: A Multidisciplinary Review

Nour Chams, Sana Chams, Reina Badran, Ali Shams, Abdallah Araji, Mohamad Raad, Sanjay Mukhopadhyay, Edana Stroberg, Eric J Duval, Lisa M Barton, Inaya Hajj Hussein, Nour Chams, Sana Chams, Reina Badran, Ali Shams, Abdallah Araji, Mohamad Raad, Sanjay Mukhopadhyay, Edana Stroberg, Eric J Duval, Lisa M Barton, Inaya Hajj Hussein

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus that is responsible for the 2019-2020 pandemic. In this comprehensive review, we discuss the current published literature surrounding the SARS-CoV-2 virus. We examine the fundamental concepts including the origin, virology, pathogenesis, clinical manifestations, diagnosis, laboratory, radiology, and histopathologic findings, complications, and treatment. Given that much of the information has been extrapolated from what we know about other coronaviruses including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), we identify and provide insight into controversies and research gaps for the current pandemic to assist with future research ideas. Finally, we discuss the global response to the coronavirus disease-2019 (COVID-19) pandemic and provide thoughts regarding lessons for future pandemics.

Keywords: COVID-19; SARS-CoV-2; coronavirus; global health; pandemic; respiratory infection.

Copyright © 2020 Chams, Chams, Badran, Shams, Araji, Raad, Mukhopadhyay, Stroberg, Duval, Barton and Hajj Hussein.

Figures

Figure 1
Figure 1
COVID-19: timeline to pandemic. The sequence of events from the outbreak in Wuhan, China to the declaration of the COVID-19 pandemic. BALF, bronchoalveolar lavage fluid.
Figure 2
Figure 2
SARS-CoV-2 structure. Viral structure with its protein components and viral RNA (vRNA).
Figure 3
Figure 3
COVID-19 pathogenesis. 1. A. SARS-CoV-2 enters the epithelial cell either via endocytosis or by membrane fusion through binding to ACE2 receptor and releasing its RNA into the cytoplasm. B. Viral RNA uses the cell's machinery to translate its viral non-structural and structural proteins and replicate its RNA. C. Viral structural proteins S, E, and M assemble in the rough endoplasmic reticulum (RER). D. Viral structures and nucleocapsid subsequently assemble in the endoplasmic reticulum golgi intermediate (ERGIC). E. New virion packed in golgi vesicles fuse with the plasma membrane and get released via exocytosis. 2. SARS-CoV-2 infection induces inflammatory factors that lead to activation of macrophages and dendritic cells. 3. Antigen presentation of SARS-CoV-2 via major histocompatibility complexes I and II (MHC I and II) stimulates humoral and cellular immunity resulting in cytokine and antibody production. 4. In severe COVID-19 cases, the virus reaches the lower respiratory tract and infects type II pneumocytes leading to apoptosis and loss of surfactant. The influx of macrophages and neutrophils induces a cytokine storm. Leaky capillaries lead to alveolar edema. Hyaline membrane is formed. All of these pathological changes result in alveolar damage and collapse, impairing gas exchange.
Figure 4
Figure 4
The association between SARS-CoV-2 and the Renin-Angiotensin-Aldosterone System (RAAS). SARS-CoV-2 binds to ACE2 receptor and enters into the cell. It has been hypothesized that this process leads to down-regulation of surface ACE2, resulting in unopposed angiotensin II buildup and activity, leading to a pro-inflammatory cascade. Alternative hypotheses are further described in the text. The uncertainties regarding the role of ACE-Is and ARBs in COVID-19 are also discussed. Ang, angiotensin; ACE, angiotensin-converting enzyme; AT1, angiotensin II type 1 receptor.
Figure 5
Figure 5
COVID-19 lung autopsy specimen. This figure is original and based on data from (46). It demonstrates COVID-19 pathology as seen in the lungs of an autopsied case (case 1, Barton et al.). (A) Diffuse alveolar damage. The arrow points to a hyaline membrane. (B) Interstitial lymphocytic inflammatory infiltrate. The arrow indicates lymphocytes within an alveolar septum. Hematoxylin-eosin stain, 200×, both images.
Figure 6
Figure 6
Small blood vessels in various organs in COVID-19. This figure is original and based on data from (46). No thrombi are seen in the small blood vessels of the (A) Lung. (B) Heart. (C) Kidney (glomerulus). (D) Liver (portal tract) (autopsy case 1, Barton et al.).
Figure 7
Figure 7
COVID-19 positive patient chest computed tomography (CT). This figure is original and illustrates the findings from (76). It demonstrates bilateral, predominately peripheral, patchy ground-glass opacities consistent with multi-lobar pneumonia.
Figure 8
Figure 8
COVID-19 positive patient chest x-ray (CXR). This figure is original and illustrates the findings from (78). It demonstrates bilateral predominately mid to lower lung field airspace opacities.

References

    1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. (2019) 17:181–92. 10.1038/s41579-018-0118-9
    1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270–3. 10.1038/s41586-020-2012-7
    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. 10.1056/NEJMoa2001017
    1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. (2020) 26:450–2. 10.1038/s41591-020-0820-9
    1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. . Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. (2020) 382:1199–207. 10.1056/NEJMoa2001316
    1. Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci. (2020) 16:1678–85. 10.7150/ijbs.45053
    1. World Health Organization . Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). (2020). Available online at: (accessed April 14, 2020).
    1. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. (2020) 25:278–80. 10.1111/tmi.13383
    1. World Health Organization WHO Timeline - COVID-19. (2020). Available online at: (accessed April 20, 2020).
    1. Holshue ML, Debolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. (2020) 382:929–36. 10.1056/NEJMoa2001191
    1. World Health Organization Coronavirus Disease (COVID-19) Pandemic. (2020). Available online at: (accessed June 11, 2020).
    1. World Health Organization Summary of Probable SARS Cases With Onset of Illness From 1 November 2002 to 31 July 2003. (2020). Available online at: (accessed April 16, 2020).
    1. World Health Organization Middle East Respiratory Syndrome Coronavirus (MERS-CoV). (2020). Available online at: (accessed April 16, 2020).
    1. Onder G, Rezza G, Brusaferro S. Case-fatality rate characteristics of patients dying in relation to COVID-19 in Italy. JAMA. (2020) 323:1775–6. 10.1001/jama.2020.4683
    1. Wong ACP, Li X, Lau SKP, Woo PCY. Global epidemiology of bat coronaviruses. Viruses. (2019) 11:174. 10.3390/v11020174
    1. Lam TT, Shum MH, Zhu HC, Tong YG, Ni XB, Liao YS, et al. . Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. (2020) 583:282–5. 10.1038/s41586-020-2169-0
    1. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. (2011) 81:85–164. 10.1016/B978-0-12-385885-6.00009-2
    1. Perlman S. Another decade, another coronavirus. N Engl J Med. (2020) 382:760–2. 10.1056/NEJMe2001126
    1. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. (2006) 66:193–292. 10.1016/S0065-3527(06)66005-3
    1. World Health Organization Modes of Transmission of Virus Causing COVID-19: Implications for IPC Precaution Recommendations. (2020). Available online at: (accessed June 11, 2020).
    1. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. . Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. (2020) 382:2081–90. 10.1056/NEJMoa2008457
    1. Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. . Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis. (2020) 20:410–1. 10.1016/S1473-3099(20)30114-6
    1. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen LJ, et al. . Presumed asymptomatic carrier transmission of COVID-19. JAMA. (2020) 323:1406–07. 10.1001/jama.2020.2565
    1. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. (2020) 26:1470–7. 10.3201/eid2607.200282
    1. Bauch CT, Lloyd-Smith JO, Coffee MP, Galvani AP. Dynamically modeling SARS and other newly emerging respiratory illnesses: past, present, and future. Epidemiology. (2005) 16:791–801. 10.1097/01.ede.0000181633.80269.4c
    1. Choi S, Jung E, Choi BY, Hur YJ, Ki M. High reproduction number of Middle East respiratory syndrome coronavirus in nosocomial outbreaks: mathematical modelling in Saudi Arabia and South Korea. J Hosp Infect. (2018) 99:162–8. 10.1016/j.jhin.2017.09.017
    1. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. (2020) 55:2000607. 10.1183/13993003.00607-2020
    1. Mossel EC, Wang J, Jeffers S, Edeen KE, Wang S, Cosgrove GP, et al. . SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology. (2008) 372:127–35. 10.1016/j.virol.2007.09.045
    1. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, Van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. (2004) 203:631–7. 10.1002/path.1570
    1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. (2020) 24:91–8. 10.1016/j.jare.2020.03.005
    1. Cheng A, Zhang W, Xie Y, Jiang W, Arnold E, Sarafianos SG, et al. . Expression, purification, and characterization of SARS coronavirus RNA polymerase. Virology. (2005) 335:165–76. 10.1016/j.virol.2005.02.017
    1. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. (2020) 10:102–8. 10.1016/j.jpha.2020.03.001
    1. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. (2020) 92:424–32. 10.1002/jmv.25685
    1. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. (2012) 76:16–32. 10.1128/MMBR.05015-11
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. 10.1016/S0140-6736(20)30183-5
    1. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. (2020) 55:105954. 10.1016/j.ijantimicag.2020.105954
    1. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. medRxiv [Preprint]. (2020). 10.1101/2020.03.30.20048058
    1. To KK, Tsang O T, Leung WS, Tam AR, Wu TC, Lung DC, et al. . Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. (2020) 20:565–74. 10.1016/S1473-3099(20)30196-1
    1. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications. Preprint repository name; (2020). Available online at: (accessed April 16, 2020).
    1. Vaduganathan M, Vardeny O, Michel T, Mcmurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med. (2020) 382:1653–9. 10.1056/NEJMsr2005760
    1. Sanchis-Gomar F, Lavie C, Perez-Quilis C, Henry B, Lippi G. Angiotensin-converting enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in coronavirus disease 2019. Mayo Clinic Proceedings. (2020) 95:1222–30. 10.1016/j.mayocp.2020.03.026
    1. Patel AB, Verma A. COVID-19 angiotensin-converting enzyme inhibitors angiotensin receptor blockers: what is the evidence? JAMA. (2020) 323:1769–70. 10.1001/jama.2020.4812
    1. Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. (2020). 10.1001/jamacardio.2020.1624. [Epub ahead of print].
    1. Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19. BMJ. (2020) 369:m1313. 10.1136/bmj.m1313
    1. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. . Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. (2020) 217:e20200652. 10.1084/jem.20200652
    1. Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol. (2020) 153:725–33. 10.1093/ajcp/aqaa062
    1. Karami P, Naghavi M, Feyzi A, Aghamohammadi M, Novin MS, Mobaien A, et al. . Mortality of a pregnant patient diagnosed with COVID-19: a case report with clinical, radiological, and histopathological findings. Travel Med Infect Dis. (2020). 10.1016/j.tmaid.2020.101665. [Epub ahead of print].
    1. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. . Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. (2020) 220:1–13. 10.1016/j.trsl.2020.04.007
    1. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung acncer. J Thorac Oncol. (2020) 15:700–4. 10.20944/preprints202002.0220.v2
    1. Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. . Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. (2020) 33:1007–14. 10.20944/preprints202003.0311.v1
    1. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. . Endothelial cell infection and endotheliitis in COVID-19. Lancet. (2020) 395:1417–8. 10.1016/S0140-6736(20)30937-5
    1. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. (2020) 8:420–2. 10.1016/S2213-2600(20)30076-X
    1. Askin FB, Katzenstein AL. Pneumocystis infection masquerading as diffuse alveolar damage: a potential source of diagnostic error. Chest. (1981) 79:420–2. 10.1378/chest.79.4.420
    1. Parambil JG, Myers JL, Aubry MC, Ryu JH. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest. (2007) 132:50–7. 10.1378/chest.07-0104
    1. Mukhopadhyay S, Philip AT, Stoppacher R. Pathologic findings in novel influenza A (H1N1) virus (“Swine Flu”) infection: contrasting clinical manifestations and lung pathology in two fatal cases. Am J Clin Pathol. (2010) 133:380–7. 10.1309/AJCPXY17SULQKSWK
    1. Mukhopadhyay S, Mehrad M, Dammert P, Arrossi AV, Sarda R, Brenner DS, et al. . Lung biopsy findings in severe pulmonary illness associated with e-cigarette use (vaping). Am J Clin Pathol. (2020) 153:30–9. 10.1093/ajcp/aqz182
    1. Mukhopadhyay S, Parambil JG. Acute interstitial pneumonia (AIP): relationship to Hamman-Rich syndrome, diffuse alveolar damage (DAD), and acute respiratory distress syndrome (ARDS). Semin Respir Crit Care Med. (2012) 33:476–85. 10.1055/s-0032-1325158
    1. Harms PW, Schmidt LA, Smith LB, Newton DW, Pletneva MA, Walters LL, et al. . Autopsy findings in eight patients with fatal H1N1 influenza. Am J Clin Pathol. (2010) 134:27–35. 10.1309/AJCP35KOZSAVNQZW
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20. 10.1056/NEJMoa2002032
    1. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. . Covid-19 in critically ill patients in the Seattle region - case series. N Engl J Med. (2020) 382:2012–22. 10.1056/NEJMoa2004500
    1. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, Mcginn T, Davidson KW, et al. . Presenting characteristics, comorbidities, outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. (2020) 323:2052–9. 10.1001/jama.2020.6775
    1. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. . Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. (2020). 10.1093/cid/ciaa330. [Epub ahead of print].
    1. Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis. (2020) 221:1770–4. 10.1093/infdis/jiaa119
    1. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. (2020) 25:2000180. 10.2807/1560-7917.ES.2020.25.10.2000180
    1. Centers for Disease Control and Prevention Coronavirus Disease 2019 (COVID-19). (2020). Available online at: (accessed April 13, 2020).
    1. World Health Organization Laboratory Testing for Coronavirus Disease 2019 (COVID-19) In Suspected Human Cases: Interim Guidance, 19 March 2020. (2020). Available online at: (accessed April 13, 2020).
    1. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. (2020). 10.1148/radiol.2020200343. [Epub ahead of print].
    1. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. . Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. (2020) 323:1843–4. 10.1001/jama.2020.3786
    1. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. (2020). 10.1093/cid/ciaa344. [Epub ahead of print].
    1. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. (2020) 26:845–8. 10.1038/s41591-020-0897-1
    1. Dohla M, Boesecke C, Schulte B, Diegmann C, Sib E, Richter E, et al. Rapid poist-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. Public Health. (2020) 182:170–2. 10.1016/j.puhe.2020.04.009
    1. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. . Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. (2020) 80:656–5. 10.1016/j.jinf.2020.03.041
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. 10.1016/S0140-6736(20)30566-3
    1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. (2020) 18:844–7. 10.1111/jth.14768
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–9. 10.1001/jama.2020.1585
    1. Kanne JP, Little BP, Chung JH, Elicker BM, Ketai LH. Essentials for radiologists on COVID-19: an update-radiology scientific expert panel. Radiology. (2020). 10.1148/radiol.2020200527. [Epub ahead of print].
    1. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. . Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. (2020) 20:425–34. 10.1016/S1473-3099(20)30086-4
    1. Jacobi A, Chung M, Bernheim A, Eber C. Portable chest X-ray in coronavirus disease-19 (COVID-19): a pictorial review. Clinical Imaging. (2020) 64:35–42. 10.1016/j.clinimag.2020.04.001
    1. Wu Z, Mcgoogan JM. Characteristics of important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control Prevention. JAMA. (2020) 323:1239–42. 10.1001/jama.2020.2648
    1. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. (2019) 181:77–83. 10.1016/j.thromres.2019.07.013
    1. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. (2020) 18:1094–9. 10.1111/jth.14817
    1. Klok FA, Kruip JHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Res. (2020) 191:145–7. 10.1016/j.thromres.2020.04.013
    1. Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J, et al. . Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevelance, risk factors, outcome. Circulation AHA. (2020) 142:114–128. 10.1161/CIRCULATIONAHA.120.046702
    1. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism COVID-19 pneumonia: a random association? Eur Heart J. (2020) 41:1858. 10.1093/eurheartj/ehaa254
    1. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. . Clinical characteristics of Covid-19 in New York City. N Engl J Med. (2020) 382:2372–4. 10.1056/NEJMc2010419
    1. Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishyili T, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. (2020) 69:382–6. 10.15585/mmwr.mm6913e2
    1. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. . High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). (2020) 28:1195–99. 10.1002/oby.22831
    1. Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. (2020) 20:630–1. 10.1016/S1473-3099(20)30257-7
    1. KCDC . The Updates on COVID-19 in Korea as of 5 April. (2020). Available online at: (accessed April 5, 2020).
    1. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. . In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. (2020) ciaa237. 10.1093/cid/ciaa237
    1. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. (2020) 14:72–3. 10.5582/bst.2020.01047
    1. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. (2020) 323:2493–502. 10.1001/jama.2020.8630
    1. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. (2020) NEJMoa2016638 10.1056/NEJMoa,2016638
    1. U. S., Food, and Drug Administration Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. (2020). Available online at: (accessed June 15, 2020).
    1. Amsden GW. Anti-inflammatory effects of macrolides–an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. (2005) 55:10–21. 10.1093/jac/dkh519
    1. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. . Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. (2020). 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print].
    1. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. (2020) 50:348 10.1016/j.medmal.2020.03.006
    1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. (2020) 30:269–71. 10.1038/s41422-020-0282-0
    1. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. . Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. (2020) 382:2327–36. 10.1056/NEJMoa2007016
    1. Groneberg DA, Poutanen SM, Low DE, Lode H, Welte T, Zabel P. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis. (2005) 5:147–55. 10.1016/S1473-3099(05)70022-0
    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. (2020) 382:1787–99. 10.1056/NEJMoa2001282
    1. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. (2020) 14:58–60. 10.5582/ddt.2020.01012
    1. Mehta P, Mcauley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020) 395:1033–4. 10.1016/S0140-6736(20)30628-0
    1. Tay MYF, Fraser JE, Chan WKK, Moreland NJ, Rathore AP, Wang C, et al. . Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res. (2013) 99:301–6. 10.1016/j.antiviral.2013.06.002
    1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. (2020) 178:104787. 10.1016/j.antiviral.2020.104787
    1. Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. . The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. Antiviral Res. (2020) 177:104760. 10.1016/j.antiviral.2020.104760
    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. (2020) 395:473–5. 10.1016/S0140-6736(20)30317-2
    1. Lewis SR, Pritchard MW, Thomas CM, Smith AF. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev. (2019) 7:CD004477. 10.1002/14651858.CD004477.pub3
    1. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. . Effect of Dexamethasone in Hospitalized Patients With COVID-19 – Preliminary Report. (2020). Available online at: (accessed June 23, 2020).
    1. World Health Organization WHO Welcomes Preliminary Results About Dexamethasone Use in Treating Critically Ill COVID-19 Patients. (2020). Available online at: (accessed June 23, 2020).
    1. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. . Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. (2020) 117:9490–6. 10.1073/pnas.2004168117
    1. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. . Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. (2020) 323:1582–89. 10.1001/jama.2020.4783
    1. U. S., and Food Drug Administration Investigational COVID-19 convalescent plasma - emergency INDs. (2020). Available online at: (accessed April 13 2020).
    1. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. . ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. (2020) 18:1023–26. 10.1111/jth.14810
    1. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storn in acute respiratory distress syndrome. Pharma Nutr. (2020) 12:100190. 10.1016/j.phanu.2020.100190
    1. Fowler AA, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A. Effect of vitamin C. JAMA. (2019) 322:1261–70. 10.1001/jama.2019.11825
    1. Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia. (2020). Available online at: (accessed June 23, 2020).
    1. Te Velthuis AJ, Van Den Worm SH, Sims AC, Baric RS, Snijder EJ, Van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. (2010) 6:e1001176. 10.1371/journal.ppat.1001176
    1. A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection (HELPCOVID-19). (2020). Available online at: (accessed June 23, 2020).
    1. Fidan C, Aydogdu A. As a potential treatment of COVID-19: montelukast. Med Hypotheses. (2020) 142:109828. 10.1016/j.mehy.2020.109828
    1. The COVID-19 Symptom Motelukast Trial (COSMO). (2020). Available online at: (accessed June 23, 2020).
    1. Le TT, Andreadakis Z, Kumar A, Román RG, Tollefsen S, Saville M, et al. . The COVID-19 vaccine development landscape. Nat Rev Drug Disc. (2020) 19:305–6. 10.1038/d41573-020-00073-5
    1. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19). (2020). Available online at: (accessed April 16, 2020).
    1. Patel A, Jernigan DB, Nco VCDCRT. Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep. (2020) 69:140–6. 10.15585/mmwr.mm6905e1
    1. Sohrabi C, Alsafi Z, O'neill N, Khan M, Kerwan A, Al-Jabir A, et al. . World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. (2020) 76:71–6. 10.1016/j.ijsu.2020.02.034
    1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. (2020) 323:709–10. 10.1001/jama.2020.1097
    1. Gostin LO, Hodge JG, Jr. US emergency legal responses to novel coronavirus: balancing public health and civil liberties. JAMA. (2020) 323:1131–2. 10.1001/jama.2020.2025
    1. CDC Implementation of Mitigation Strategies for Communities With Local COVID-19 Transmission. (2020). Available online at: (accessed April 18, 2020).
    1. Friston KJ, Parr T, Zeidman P, Razi A, Flandin G, Daunizeau J, et al. Second Waves, Social Distancing, and the Spread of COVID-19 Across America. (2020). Available at: (accessed June 27, 2020).
    1. Aleta A, Martin-Corral D, Piontti AP, Ajelli M, Litvinova M, Chinazzi M, et al. . Modeling the Impact of Social Distancing, Testing, Contact Tracing and Household Quarantine on Second-Wave Scenarios of the COVID-19 Pandemic. (2020). Available at: (accessed June 27, 2020).
    1. Hick JL, Biddinger PD. Novel coronavirus and old lessons - preparing the health system for the pandemic. N Engl J Med. (2020) 382:e55. 10.1056/NEJMp2005118

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe